IUL Study A Randomized Sham - Controlled Clinical Study

Intraurethral Laser Therapy for Stress Urinary Incontinence: A Randomized Sham - Controlled Clinical Study

Primary aim of the study is to compare the impact of SUI on the VAS (visual analogue scale) 3 months after laser therapy versus sham laser therapy.

Study Overview

• Status: Recruiting
• Conditions: Stress Urinary Incontinence
• Intervention / Treatment: Device: Intraurethral laser therapy; Device: Intraurethral SHAM laser therapy

Detailed Description

Background: Stress urinary incontinence (SUI) has a huge impact on the quality of life (QoL) in women and its treatment is challenging. Intraurethral laser may be an additional treatment option.

Study aim: The aim is to study the effectiveness of intraurethral laser therapy in women with SUI.

Design: randomized double blinded sham - controlled clinical study

Study population: women which have been diagnosed with SUI I-II°, aged between 18-80 years.

Study groups: Participants will be randomized (1:1), without stratification. The Intervention group will receive 2 treatments of intraurethral laser therapy and the Control group will receive 2 treatments of intraurethral SHAM laser therapy.

Sample size: A sample size of 20 women, 8 per group including a 20% Drop Out Rate, was calculated.

Primary outcome: impact of SUI on the VAS scale 3 months after laser therapy versus sham laser therapy.

Secondary study outcomes were defined as subjective SUI, objective SUI, QoL, treatment satisfaction, intraurethral microbiome, 3 months after laser therapy versus sham laser therapy.

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Daniela Gold, MD PhD; Phone Number: 0043316 385 81437; Email: daniela.gold@medunigraz.at

Study Locations

• Austria
  • Styria
    • Graz, Styria, Austria, 8036
      • Recruiting
      • Departement of Obstetrics and Gynecology
      • Contact: Daniela Gold, MD PhD; Phone Number: 0043316 385 81437; Email: daniela.gold@medunigraz.at
      • Sub-Investigator: Karl Tamussino, M.D.
      • Sub-Investigator: Gerda Trutnovsky, M.D.
      • Sub-Investigator: Anna-Maria Schütz, M.D.
      • Sub-Investigator: Nadja Taumberger, M.D.
      • Principal Investigator: Daniela Gold, M.D. PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Female between 18 and 80 years
• Confirmed SUI through cough stress test within the last 24 months
• SUI I-II° for more than 6 months
• At least one incontinence episode per 24 hour period measured over three days according to a bladder diary
• Valsalva leak-point pressure (VLPP) ≤60 cm H2O
• Maximum cystometric capacity ≥250 mL
• No pelvic surgery within last 6 months (including prolapse repair, subjects who have residual or recurrent SUI following colposuspension or a sling procedure may be included in the study if the procedure was conducted at least 6 months prior to screening /baseline visit)
• BMI (body mass index) ≤35 kg/m2
• Willing to give informed consent and complete the follow up schedule

Exclusion Criteria:

• Active lower urinary tract infections (urethritis, cystitis or vaginitis)
• Three (3) or more cultured-proven bacterial urinary tract infection (UTI) in the last 12 months
• Detrusor overactivity on urodynamics
• Postvoiding residual (PVR) > 100 ml
• Previous urethral surgery (i.e. fistula or diverticula)
• Pelvic organ prolapse grade > 3 as defined by POP-Q and symptomatic
• Known polyuria (>3l/24h)
• Unevaluated macro hematuria
• Neurogenic bladder
• Evidence of dysplasia in a Pap smear (done in the last 24 months)
• Tumours of the Urinary tract
• Previous radiation or brachytherapy to treat pelvic cancer
• Uncontrolled diabetes
• Active herpes genitalis
• Pregnancy
• Vaginal delivery within 6 months prior to the Screening/Baseline Visit

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Intraurethral laser therapy; Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic fluid (Cathejell ®) will be applied to the urethral meatus. Before laser therapy, an intraurethral swab will be taken before treatment in order to determine the intraurethral microbiome. Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Incontinence mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2.	Device: Intraurethral laser therapy; The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.; Other Names: Fotona smooth XS laser
Placebo Comparator: Intraurethral SHAM laser therapy; Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the "normal" probe. The treating physician will not be aware of the study allocation and the type of probe in use.	Device: Intraurethral SHAM laser therapy; The laser will be applied according to the manufacturer's protocol. This includes a 2 step laser treatment using 2 different modes at 2 timepoints. The treatment takes about 15 minutes time.; Other Names: Fotona smooth XS laser

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Subjective symptoms of SUI	A visual analogue scale (VAS) is used for assessment for the subjective symptoms and improvement of SUI. Patients are asked to indicate the degree of their symptoms on a scle ranging from 0 (no symptoms) to 10 (worst possible symptoms).	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Degree of pain during laser therapy on a visual analogue scale (VAS)	Patients are asked to indicate the degree of pain during laser therapy on a visual analogue scale (VAS) ranging from 0 (no pain) to 10 (worst possible pain).	3 months
Subjective SUI	Subjective SUI as determined by the question "do you leak urine when coughing, sneezing or laughing" with the answer possibilities of "Yes" and "No".	3 months
Objective SUI	Objective SUI as determined by the cough stress test at 300ml bladder filling, which will either be positive or negative.	3 months
Patient Global Impression of Improvement	The PGI-I scales are robust and valid instruments to assess disease severity, bother and improvement after treatment in women and will be used to determine the Patient Global Impression of Improvement. The PGI-I consists of a 7-likert-scale with 7 being the worst bother.	3 months
Patient Global Impression of Severity	The Patient Global Impression of Severity (PGI-S) is a global index that may be used to rate the severity of a specific condition (in a single-state scale). The PGI-I scales are robust and valid instruments to assess disease severity, bother and improvement after treatment in women and will be used to determine the Patient Global Impression of Severity. The PGI scales are robust and valid instruments to assess disease severity, bother and improvement after treatment. The patient can choose from 4 answers including none, mild, moderate and severe.	3 months
Quality of Life using the Kings Health Questionnaire	The Kings Health Questionnaire was validated in women with stress urinary incontinence and assesses the impact of incontinence on quality of life. The eight subscales ("domains") scored between 0 (best) and 100 (worst). The Symptom Severity scale is scored from 0 (best) to 30 (worst); lower scores indicate better QoL. Success in terms of the study is defined as 10 points improvement on the total Kings Health Questionnaire score.	3 months
Pelvic floor symptoms	A validated self-administered pelvic floor questionnaire (Baessler) will be used to assess urogentinal symptoms. Questions regarding bladder (15), bowel (12), and sexual function (10), and pelvic organ prolapse symptoms (five) are grouped according to the physiological functions of the pelvic floor: bladder function, bowel function, prolapse symptoms, and sexual function domains. Quality of life measures and bothersomeness ratings were integrated into the four domains. Frequency, severity, and bothersomeness of pelvic floor symptoms are assessed using a four-point scoring system for most items in the questionnaire, apart from defecation frequency, bowel consistency, sufficient lubrication, and the reason for sexual abstinence. The lower the score the less pelvic floor symptoms the patients have.	3 months
Pad Weight	In regards to the one-hour stress pad weight test women are asked to drink 500 ml of sodium-free liquid in <15 min, then sit, walk for 30 min including climbing one flight of stairs. Afterwards the total amount of urine leaked is determined by weighing the pad. Lower weight means less urine loss.	3 months
Patient satisfaction with treatment/inpatient management	Patient satisfaction will be evaluated with the "Fragebogen zur Patientenzufriedenheit - ZUF-8". The German version of the original "Client Satisfaction Questionnaire-CSQ8", is a validated tool for measuring global patient satisfaction at the end of inpatient treatment. The ZUF-8 is an 8-items questionnaire to assess satisfaction in patients undergoing inpatient treatment. At 3 months treatment satisfaction will be assessed using an adopted version of the questionnaire. The lower the score, the higher is the patient satisfaction.	3 months
Microbiome	Extraction of archaeal/bacterial 16S rRNA gene using the Illumina MiSeq platform in order to determine the intraurethral microbiome	3 months

Collaborators and Investigators

• Sponsor: Medical University of Graz

Study record dates

Study Major Dates

• Study Start (Actual): January 8, 2021
• Primary Completion (Estimated): January 1, 2025
• Study Completion (Estimated): January 1, 2025

Study Registration Dates

• First Submitted: January 12, 2021
• First Submitted That Met QC Criteria: January 12, 2021
• First Posted (Actual): January 13, 2021

Study Record Updates

• Last Update Posted (Estimated): January 18, 2024
• Last Update Submitted That Met QC Criteria: January 17, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: Stress urinary incontinence; Laser therapy; intraurethral
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Urologic Diseases; Lower Urinary Tract Symptoms; Urological Manifestations; Urination Disorders; Elimination Disorders; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Urinary Incontinence; Enuresis; Urinary Incontinence, Stress
• Other Study ID Numbers: V1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No